The membrane was pre-hybridized/hybridized with MiracleHyb Hybridization solution according to the instruction manual (Stratagene). plays an essential role in mediating Ang II-induced cardiac hypertrophy, whereas overexpression of Trx1 inhibited Ang II-induced upregulation of cyclin D2. miR-98 decreased both expression of cyclin D2 and the activity of a cyclin D2 3UTR luciferase reporter, suggesting that both Trx1 and miR-98 negatively regulate cyclin D2. Overexpression of cyclin D2 attenuated the suppression of Ang II-induced cardiac hypertrophy by Presatovir (GS-5806) miR-98, suggesting that the anti-hypertrophic actions of miR-98 are mediated in part by Presatovir (GS-5806) downregulation of cyclin D2. == Conclusions == These results suggest that Trx1 upregulates expression of the let-7 family, Presatovir (GS-5806) including miR-98, which in turn inhibits cardiac hypertrophy, in part through downregulation of cyclin D2. Keywords:microRNA, thioredoxin, cardiac hypertrophy, cyclin D2 Thioredoxin 1 (Trx1) is a ubiquitously expressed anti-oxidant which has two cysteine residues in its catalytic center1. When the Presatovir (GS-5806) cysteine residues in Trx1 are reduced in the presence of NADPH and Trx reductase, they are highly reactive with oxidized proteins with a disulfide bond and reduce them via thiol disulfide exchange reactions. Trx1 reacts with a plethora of proteins, thereby controlling a wide variety of cellular functions, including growth, death and inflammation, through transcription, protein-protein interaction and posttranslational modifications2. One of the most prominent actions of Trx1 in the heart is suppression of cardiac hypertrophy. Overexpression of wild-type Trx1 in mice reduces cardiac hypertrophy induced by pressure-overload, whereas a mutated Trx1 (which inhibits endogenous Trx1 activity) increases hypertrophy3. Together with its cell protective actions in the heart, Trx1 could be a promising modality to treat pathological hypertrophy and inhibit the progression of heart failure. Previous investigations by us and other investigators have suggested that Trx1 inhibits pathological hypertrophy through multiple mechanisms. For example, Trx1 inhibits Ras3and ASK-14, thereby negatively regulating protein kinase cascades known to stimulate hypertrophy. In the nucleus, Trx1 inhibits NF-B, thereby inhibiting hypertrophy, but stimulates CREB and Nrf1, thereby stimulating cell survival in the heart5. We have shown recently that Trx1 induces nuclear localization of class II HDACs, through reduction of evolutionarily conserved cysteine residues6, thereby inhibiting pathological hypertrophy. Judging from the fact that Trx1 DDR1 is universally protective and affects a wide variety of signaling molecules and transcription factors, we speculated that Trx1 may inhibit cardiac hypertrophy through regulation of microRNA (miRNA) as well. miRNAs are naturally existing small noncoding RNA molecules ~22nt in length. Mature miRNAs negatively regulate gene expression by either translational repression or mRNA degradation7. To date, several miRNAs have been identified that affect cardiac hypertrophy and heart failure8. For example, miR-19and miR-13310negatively regulate cardiac hypertrophy, whereas miR-19511induces pathological hypertrophy and heart failure. miR-23a and miR-208a also positively regulate cardiac hypertrophy12,13, and miR-21 regulates growth and survival of cardiomyocytes and fibroblasts, thereby positively mediating cardiac hypertrophy14,15. In order to evaluate the involvement of miRNAs in mediating the anti-hypertrophic actions of Trx1, we conducted microarray analyses of miRNA. We found that members of the let-7 family, including miR-98, are upregulated in hearts of transgenic mice with cardiac specific overexpression of Trx1 (Tg-Trx1). Since members of the let-7 family inhibit cell growth responses and Presatovir (GS-5806) are recognized as tumor suppressors16, we hypothesized that the anti-hypertrophic actions of Trx1 in the heart and cardiomyocytes therein are mediated in part by upregulation of miR-98. Let-7 was one of the first miRNAs identified and cloned inC. elegans, and its presence is evolutionarily conserved16. Furthermore, let-7 is downregulated in proliferating cell types, whereas it is relatively abundant in mature tissues16. However, the function of let-7 is not well.